Physician profile
Terrence Coulter
NPI 1477591303
$6,579.28
in general payments reported to CMS, 2019-2025
46 companies · $1,002 in 2025
The $1,002 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,505 · 2020: $311 · 2021: $26.84 · 2022: $1,908 · 2023: $875 · 2024: $950 · 2025: $1,002.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,768 · Education: $59.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,767.71 |
| Education | $59.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,874.54 | 2022-2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $751.01 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $484.23 | 2019-2025 | Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $375.83 | 2019-2025 | Ofev, Jascayd |
| Genentech USA, INC. | $289.25 | 2019-2025 | Xolair |
| Grifols USA, LLC | $249.20 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Jazz Pharmaceuticals INC. | $223.39 | 2019-2025 | |
| United Therapeutics Corporation | $218.54 | 2019-2025 | Tyvaso, Tyvaso |
| Regeneron Healthcare Solutions, INC. | $185.71 | 2019-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $157.48 | 2019-2024 | Opsumit, Uptravi |
| Mylan Specialty L.P. | $127.17 | 2019-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $126.83 | 2019-2025 | |
| Insmed, INC. | $125.05 | 2022-2025 | Arikayce |
| Genzyme Corporation | $116.52 | 2024-2025 | |
| Axsome Therapeutics, INC. | $100.56 | 2023-2025 | Sunosi |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $97.35 | 2022-2024 | Kcentra |
| Circassia INC. | $85.40 | 2019 | |
| Merck Sharp & Dohme LLC | $83.33 | 2019-2025 | Zerbaxa |
| Abbvie INC. | $72.63 | 2022-2024 | |
| Baxter Healthcare | $67.51 | 2023-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Pfizer INC. | $56.19 | 2019-2025 | |
| Idorsia Pharmaceuticals US INC | $53.83 | 2022-2024 | Quviviq |
| Philips North America LLC | $47.96 | 2019-2023 | |
| Avadel Cns Pharmaceuticals, LLC | $46.96 | 2023-2024 | Lumryz |
| Mallinckrodt Hospital Products INC. | $46.09 | 2024 | Acthar |
| Sunovion Pharmaceuticals INC. | $43.91 | 2019 | |
| Portola Pharmaceuticals, LLC | $42.91 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $39.21 | 2023-2024 | Purified Cortrophin Gel |
| Viatris Specialty LLC | $32.94 | 2025 | Yupelri |
| Lilly USA, LLC | $32.88 | 2025 | Zepbound |
| Electromed, INC. | $29.85 | 2019 | |
| Amgen INC. | $28.80 | 2024 | Tezspire |
| Apria Healthcare LLC | $26.84 | 2021 | |
| Allergan, INC. | $25.78 | 2019-2020 | |
| Harmony Biosciences LLC | $24.70 | 2023 | Wakix |
| Regeneron Pharmaceuticals, INC. | $24.44 | 2024 | Dupixent |
| Intuitive Surgical, INC. | $23.51 | 2022 | |
| Livanova USA, INC. | $20.92 | 2019 | |
| Shionogi INC | $20.59 | 2024 | Fetroja |
| Siemens Medical Solutions USA, INC. | $16.66 | 2024 | Cios Spin |
| Verona Pharma, INC. | $16.46 | 2025 | Ohtuvayre |
| Janssen Pharmaceuticals, INC | $14.29 | 2019 | |
| Astellas Pharma US INC | $13.58 | 2019 | |
| Pulmonx Corporation | $13.37 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.55 | 2022 | |
| Chiesi USA, INC. | $12.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terrence Coulter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.